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CASE REPORT
Primary Kaposi’s sarcoma of the nasal 
cavity: a case report and review of the literature
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Abstract 
Background: Kaposi sarcoma is a neoplastic vascular disorder. It usually present on the skin of the upper and lower 
extremities, rarely in the mucosa of the head and neck. The most common sites reported are within the oral cavity, 
particularly on the palate. Other mucosal sites are rare. We present an unusual case where the primary manifestation 
of the Kaposi’s sarcoma was in the nasal mucosa.
Case presentation: A 56-year-old female of Mediterranean descent presented with a 1 year history of swelling on 
the left side of her nose, nasal obstruction and occasional minor epistaxes. Physical examination showed a firm and 
bulging polypoid mass which filled the left nasal cavity without cutaneous lesions.
Computed tomography (CT) demonstrated a tumor, measuring 77 mm in diameter, occupying the left nasal cavity 
causing erosion of nasal septum and extending posteriorly to the left choana and nasopharynx. There was bilateral 
cervical lymphadenopathy. Patient treated with chemotherapy alone. She was in a complete response after the first 
cycle. The patient received no further treatment. She needs a regular medical checkups that include a review of a 
patient’s medical history and a complete physical exam. She is in excellent local control over 12 months.
Conclusions: A review of the literature revealed that only seven cases of primary Kaposi sarcoma of the nasal cavity 
have previously been published and only two of them presented in a patient not associated with the acquired immu-
nodeficiency syndrome. Here, we report the third case where the primary manifestation of the Kaposi sarcoma was in 
the nasal cavity in a patient with an adequate immune system.
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Background
Kaposi’s sarcoma (KS) is a low-grade vascular tumor 
associated with infection with human herpesvirus 8 
(HHV-8), also known as the KS-associated herpesvirus 
(KSHV) [1, 2].
The disease is named after Moritz Kaposi, a Hungarian 
dermatologist on the faculty of the University of Vienna, 
who first described the entity in 1872 as “idiopathic mul-
tiple pigmented sarcoma of the skin” [3]. The most recur-
rently affected sites are the skin and mucous membrane 
[4, 5], however, it can be found in other parts of the body: 
lungs, stomach, intestine [6–8], etc.
The KS of the head and neck usually involves the 
mucous membranes of the oral cavity, but it can be found 
in the pharynx, larynx, and tonsillar [9–18]. Isolated 
nasal location is extremely rare [19–23].
A review of the literature revealed that there are a few 
reported cases of KS involving the head and neck region. 
In fact, only seven had primary presentation in the nasal 
cavity and two of them were not AIDS related [20, 21, 
24–26].
Here, we present a case of KS of the left nasal cavity in 
HIV negative patient, treated by chemotherapy only.
Case report
A 56-year-old female of Mediterranean descent pre-
sented with a 1  year history of swelling on the left side 
of her nose, nasal obstruction and occasional minor 
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epistaxes. Physical examination showed a firm and bulg-
ing polypoid mass which filled the left nasal cavity with-
out cutaneous lesions.
Computed tomography (CT) (Fig.  1) demonstrated a 
tumor, measuring 77 mm in diameter, occupying the left 
nasal cavity causing erosion of nasal septum and extend-
ing posteriorly to the left choana and nasopharynx. There 
was bilateral cervical lymphadenopathy.
A biopsy specimen was obtained in the nasal cavity. 
Initially, the diagnosis of angiosarcoma was made. After 
multidisciplinary consultation meeting, a second patho-
logical opinion was required. Original slides examination 
revealed a submucosal proliferation composed of inter-
secting ill-defined fascicles, of spindled cells with mild 
to moderate nuclear atypia. Slit-like spaces containing 
red blood cells were noted. Intracytoplasmic and vari-
ably sized hyaline globules were seen in some tumor cells. 
Immunohistochemical study revealed a strong expression 
of CD31, CD34, and vimentin. Tumor cells showed nega-
tive staining for AE1/AE3, CK5/6, HMB-45, and melan-
A. As tissue was depleted in the paraffin block, we were 
unable to perform further immunohistochemical testing, 
using HHV 8 antibody. A final diagnosis of Kaposi’s sar-
coma was rendered.
A chest CT did not showed metastases in the lungs.
Decision in multidisciplinary consultation meeting is 
to instaure neoadjuvant chemotherapy because surgical 
excision is not feasible. Then an evaluation must be per-
formed. Chemotherapy drugs ifosfamide (IFO) and doxo-
rubicin (DOXO) was started on December 22, 2014. The 
detailed treatment regimen was as follows: IFO 1800 mg/
m2 i.v. d1-5; mesna dose is 100 % of the IFO dose (3 g) i.v. 
d1-5 and DOXO 60 mg/m2 d1.
The cycle was repeated every 21 days. Physical exami-
nation after the first cycle of treatment showed a com-
plete response. To keep the clinical response, the patient 
continued chemotherapy until four cycles. The fourth 
cycle date April 27, 2015.
Computed tomography (CT) of evaluation showed a 
near complete response in the nasal cavity (Fig. 2).
The patient received no further treatment. She 
needs a regular medical checkups that include a 
review of a patient’s medical history and a complete 
physical exam. She is in excellent local control over 
12 months.
Discussion
Sinonasal cancers, which account for 3  % of all head 
and neck cancers, have their origin in the nasal cav-
ity in 20–30  % of cases [27]. It is relatively uncommon 
[28–30], with an incidence of 0.75 per 100,000 in the 
United States. This is a heterogeneous group of uncom-
mon neoplasms including adenocarcinomas, malignant 
melanomas and non-Hodgkin’s lymphomas, followed in 
frequency by sarcomas, esthesioneuroblastomas, heman-
giopericytomas, plasmacytomas, and anaplastic carcino-
mas [31–34].
KS is an important opportunistic disease, which fre-
quently occurs in HIV-positive patients. The incidence of 
KS involving head and neck was reported to be as high 
as 40–67 %, in which the cutaneous lesions predominate 
[25, 26].
Fig. 1 a Axial CT, b Coronal CT: demonstrated a tumor occupying the left nasal cavity causing erosion of nasal septum and extending posteriorly to 
the left choana and nasopharynx
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However, the involvement of this region is only 14 % of 
patients with HIV-negative [24, 35–41].
Here, we reported a case de Kaposi’s sarcoma of the 
nasal cavity in patient with HIV-negative.
KS involvement has been observed in almost all visceral 
sites, including lymph nodes, liver, pancreas, heart, the 
testes, bone marrow, bone, skeletal muscle and mucosa of 
head and neck [42, 43].
The most frequent sites of noncutaneous disease are 
the oral cavity, gastrointestinal tract, and respiratory sys-
tem [44–48].
There is a few cases of the Kaposi’s sarcoma in the nasal 
mucosa [25, 26, 49].
In a review of the literature, seven cases of the Kaposi’s 
sarcoma in the nasal mucosa were reported.
Gnnep et al. discussed nine cases of KS arising in the 
head and neck region. One of them was in the nose-
mucocutaneous junction with HIV-negative, treated by 
surgical excision and relapsed at 9 months [24].
The second case of the KS in the nasal cavity with an 
adequate immune system was reported by Ioannis Veni-
zelos et  al. It was a case of a 59  year-old woman who 
presented a tumor arising from the left nasal septum 
which was excised. The patient received no further 
treatment and 4 years later, she is in excellent condition 
[21].
Three patients with HIV-positive who had KS of the 
nasal cavity, were treated by surgical excision. One of 
them relapsed at 2 months [20, 25, 26].
Patients with tumors of the nasal cavity usually present 
with a history of chronic sinus congestion and recurrent 
nasal obstruction. In our case, there was no ulceration of 
the overlying squamous epithelium and the patient pre-
sented with swelling on the left side of her nose, nasal 
obstruction and occasional minor epistaxes.
Various clinicopathologic forms of Kaposi’s sarcoma 
have been described, which often have overlapping 
features (patch, plaque, nodular, lymphadenopathic, 
infiltrative, florid, telangiectatic, ecchymotic, keloidal, 
angiomatous, inflammatory, pleomorphic, lymphangi-
omatous, and generalized lymphedema). In the earliest 
stage of Kaposi sarcoma, a flat lesion made of miniature 
vessels surrounding larger ectatic vessels is noted [50, 
51].
In the more advanced stage of the disease, a discern-
ible but relatively bland spindle cell component, cen-
tered around the proliferating vascular channels, can be 
described. Coalescent foci of spindle cells produce the 
classic nodular lesions of Kaposi sarcoma [51].
The spindle cells are separated by slit and sieve-like 
spaces containing erythrocytes and vascular channels. 
Lymphocytes and plasma cells, hemosiderin deposits, 
and dilated vessels are commonly seen at the periphery. 
Both intracellular and extracellular hyaline globules may 
be identified [52].
The tumor cells are strongly immunoreactive for CD31, 
CD34, factor VIII–related antigen, and Latent nuclear 
antigen-1 of HHV-8 (Kaposi sarcoma-associated herpes 
virus. They are variably immunoreactive for smooth mus-
cle actin and are negative for cytokeratins (AE1/AE3 and 
CAM 5.2). The nuclear positivity using the LANA-1 anti-
body confirms the diagnosis [50, 51, 53].
The histologic differential diagnoses of Kaposi’s sar-
coma include angiosarcoma, fibrosarcoma, arteriovenous 
malformations, and spindle cell hemangioendothelioma.
Clinicopathological features, mainly immunohisto-
chemical studies, help by excluding these differential 
diagnoses, but some cases with unusual findings can pose 
a challenge to general pathologists [50, 52, 53].
The major goals of treatment are symptom palliation, 
prevention of disease progression, and shrinkage of 
tumor to alleviate edema, organ compromise, and psy-
chological stress [54].
For HIV-positive patients who develop either limited 
or advanced Kaposi sarcoma (KS), it is recommended 
that treatment includes highly active antiretroviral ther-
apy (ART).
Local treatment modalities are useful for cosmesis or 
the management of symptomatic bulky KS lesions, but 
they do not prevent the development of new lesions in 
untreated areas. The most widely used local treatment 
approaches include:
Intralesional chemotherapy with vinblastine, radiation 
therapy and topical alitretinoin.
Fig. 2 Axial computed tomography (CT) of evaluation showed a 
near complete response in the nasal cavity
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Indications for systemic chemotherapy include exten-
sive cutaneous disease, symptomatic visceral involve-
ment, and cutaneous KS that is unresponsive to local 
therapy.
When chemotherapy is indicated, treatment with 
pegylated liposomal doxorubicin or liposomal dauno-
rubicin is generally recommended as the first-line treat-
ment for KS [55]. Other agents that have been used 
include paclitaxel, bleomycin, vinblastine, vincristine, 
and etoposide [56].
In our case, chemotherapy seems to be effective, since 
8 months later the patient is in excellent condition with-
out evidence of local recurrence or metastasis both clini-
cally and radiologically.
Conclusions
Primary Kaposi sarcoma of the nasal cavity is a very 
rare  entity. Our case represents the third reported case 
not associated with AIDS. Chemotherapy with doxoru-
bicin seems to be effective with in excellent response.
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